A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
COVID-19 meds like Paxlovid will soon have big price tags
Oct 30, 2023
The pills still will be available at no cost until those bought earlier by the federal government run out.
One in seven drug supply chain issue reports tied to drug shortages
Apr 10, 2024
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
Nirmatrelvir-ritonavir does not speed up alleviation of COVID-19 symptoms
Apr 05, 2024
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Paxlovid not helpful for reducing most post-COVID-19 conditions
Oct 31, 2023
No differences were seen in most post-COVID-19 conditions examined individually or by organ system, apart from a lower combined risk for venous thromboembolism and pulmonary embolism.
Study looks at links between anxiety disorders, benzodiazepines, dementia
Aug 14, 2023
Benzodiazepines and anxiety disorders were linked to dementia risk, but no additional risk was seen for benzodiazepines in patients with anxiety disorders.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
Risk profile IDs COVID-19 patients who will benefit from baricitinib
Feb 26, 2024
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
Fluticasone furoate does not cut time to COVID-19 symptom resolution
Sep 21, 2023
No significant reduction was seen in the percent of patients with urgent care or emergency department visits or hospitalization.